January 29, 2015 10:07 AM ET


Company Overview of Catalyst Biosciences, Inc.

Company Overview

Catalyst Biosciences, Inc., a drug discovery and development company, develops catalytic biopharmaceutical products based on engineered human proteases. It offers proteases for the treatment of a range of diseases with a focus on hemostasis and inflammation. The company provides recombinant human factor VIIa, IX, and Xa to treat hemophilia; and inflammation program that focuses on complement cascade, an activation component of inflammation. The company also provides FVIIa variants, including FVIIa proteases that allow use in a prophylactic setting for hemophilia patients and for the control of bleeding in normal patients in a surgical or trauma setting; and Alterase therapeutics for inflamma...

260 Littlefield Avenue

South San Francisco, CA 94080-7019

United States

Founded in 2002





Key Executives for Catalyst Biosciences, Inc.

Chief Executive Officer and Director
Age: 54
Co-Founder and Chairman of Scientific Advisory Board
Compensation as of Fiscal Year 2014.

Catalyst Biosciences, Inc. Key Developments

Catalyst Biosciences, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 10:00 AM

Catalyst Biosciences, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 10:00 AM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Nassim Usman, Chief Executive Officer and Director.

Catalyst Biosciences, Inc. and Isu Abxis Form Strategic Collaboration

Catalyst Biosciences, Inc. and Isu Abxis announced the companies have formed a strategic collaboration to develop Catalyst's next-generation Factor IX development candidate FIX-NG (CB 2679d) for the prevention and treatment of bleeding in hemophilia B patients. The collaboration will advance FIX-NG through IND-enabling preclinical studies, manufacturing and the completion of Phase 1 clinical studies designed to establish proof-of-mechanism for the molecule in hemophilia B patients. Under the terms of the collaboration, Isu Abxis will use its biologics manufacturing and development expertise to advance FIX-NG through preclinical and Phase 1 studies and Catalyst and Isu will collaborate and share in profits on the development and commercialization of FIX-NG worldwide. Isu will pay Catalyst an upfront licensing fee and milestone payments through the end of the Phase 1 clinical trial and holds an option to exclusively commercialize FIX-NG in Korea. Catalyst retains development and commercial ownership rights of the program outside of Korea.

Similar Private Companies By Industry

Company Name Region
Innovative Cardiovascular Solutions, LLC United States
Percivia LLC United States
TEI Biosciences Inc. United States
TriLogic Pharma LLC United States
Codagenix, Inc. United States

Recent Private Companies Transactions

Private Placement
April 9, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Catalyst Biosciences, Inc., please visit www.catalystbiosciences.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.